CuraLinc Healthcare

CuraLinc Healthcare

CuraLinc Healthcare operates as a behavioral health and employee assistance program (EAP) provider established in Chicago, Illinois. Led by CEO Charles A. Samuelson, the firm has built its footprint by serving employers, unions, and higher education institutions with a suite of mental wellness, substance use, and work-life balance solutions. The firm's genesis and subsequent scaling have been funded by Samuelson family capital, positioning it as a privately held entity with no outside equity partners — a structure that allows for clinical decision-making anchored to outcomes rather than quarterly return targets. The firm deploys capital and operational resource exclusively within digital and in-person behavioral health services. Its program architecture spans structured EAP counseling, manager referrals, legal and financial consultation, and digital cognitive behavioral therapy (iCBT) modules. The platform integrates directly into employer benefits ecosystems and health plans, serving over 15 million covered lives globally. Geographic delivery reaches North America, the United Kingdom, Ireland, and multiple markets across Asia-Pacific and Latin America via a network of licensed clinicians and local care coordinators. CuraLinc's model avoids fund-of-funds or co-investment structures, instead directly owning its technology stack and clinical network — an operational asset owner rather than a capital allocator. Headquartered in Chicago, the firm maintains a singular operational focus without satellite investment offices. Rather than building a diversified portfolio across asset classes, CuraLinc represents a concentrated, single-asset operating business held within the family office structure. Adjacent vehicles or philanthropic entities are not publicly disclosed alongside the core company. In 2023, the firm introduced Navigator, an analytics-driven platform enhancement that maps employee behavioral health journeys and measures clinical outcomes against proprietary benchmarks, reflecting a continued internal reinvestment strategy into its core product. CuraLinc's structural distinctiveness lies in its status as a non-institutional, family-held operating company in a sector increasingly dominated by venture-backed startups and large insurance carriers. Without the pressure to exit or syndicate risk to limited partners, the firm has maintained a clinical model that prioritizes longer session lengths and higher licensure standards than most marketplace competitors — a governance posture only possible under patient, single-family ownership where the balance sheet serves clinical mission rather than fund cycle.